Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
GSK620 is a bromodomain and extra terminal domain family of proteins (BET) bromodomain 2 (BD2) inhibitor (IC50s = 316.2, 79.4, 79.4, and 199.5 nM for BRD2, BRD3, BRD4, and BRDT BD2, respectively).1 It is selective for BD2 in bromodomain-containing protein 2 (BRD2), BRD3, BRD4, and BRDT over BD1 in the same BRDs (IC50s = >15,000 nM for all). GSK620 inhibits LPS-induced chemokine (C-C motif) ligand 1 (CCL1) production in isolated human whole blood (IC50 = 794.3 nM). See the Structural Genomics Consortium (SGC) website for more information.
WARNING This product is not for human or veterinary use.
1. The optimization of a novel, weak bromo and extra terminal domain (BET) bromodomain fragment ligand to a potent and selective second bromodomain (BD2) inhibitor. J. Med. Chem. 63(17), 9093-9126 (2020).